The FDA approval of daratumumab and hyaluronidase-fihj for high-risk smoldering MM shifts care beyond watchful waiting, notes Peter Voorhees, MD. AQUILA enrolled 390 high-risk patients randomized 1:1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results